The initial success of the copyright undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on unbranded versions presents a complex picture. Despite early returns were substantial, the expiration of patents and the appearance of cheaper alternatives have eroded sales. Thus, a thorough assessment of ongoing inc